Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

25.99 -0.72 (-2.70%)
Delayed Quote Updated: 1:33 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.